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The tumor de novo in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma (RCC) is problematic. We
reviewed 5 patients who experienced such a situation. Three patients had had metachronous bilateral RCC, treated with radical
nephrectomy in one kidney and nephron-sparing surgery (NSS) in the other. Two patients had had synchronous disease; one
patient had received radical nephrectomy and NSS, and the other bilateral NSS. The 5 patients had another solid mass/de novo
tumor in the residual kidney 16–88 (mean 46.8) months after surgery. For the tumor de novo in earlier years (1992–1999), one
patient underwent surgery and hemodialysis, and the other selected a conservative observation. In recent years (2000–2007), one
patient was conservatively observed; the remaining 2 received computerized-tomography-guided radiofrequency ablation, and the
local tumors were well controlled postoperatively for 20 and 12 months with their renal function unimpaired. Ablative techniques
canpotentiallystrikeabalancebetweenoncologicalandnephrologicaloutcomesinpatientswithsporadicmultipleRCC,successful
management of which was diﬃcult previously.
Copyright © 2009 Noboru Hara et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Bilateral/multiple renal cell carcinoma (RCC) is commonly
associated with hereditary disorders represented by von
Hippel-Lindau disease, a well-known familial syndrome;
recently, RCC in patients with von Hippel-Lindau disease
has been treated with well-planned, sequential nephron-
sparing approaches, since metachronous multiple occur-
rences of RCC can be predicted at the initial diagnosis
[1]. On the other hand, sporadic/nonfamilial bilateral RCC
is infrequently encountered, and its management is also
problematical; prediction of the clinical presentations such
as postoperative de novo occurrence or recurrence of disease
is impossible in sporadic cases [2, 3]. Recurrence of renal
tumors in patients who have received surgery for sporadic
bilateral RCC represents a serious situation in the era of
nephron-sparing surgery/partial nephrectomy, because it
is diﬃcult to strike a balance between oncological and
nephrological outcomes in treating such cases. Yet, their
clinical course, management, and outcome have not been
studied thus far. We reviewed 5 patients who had de novo or
recurrent renal lesions following surgery for metachronous
or synchronous bilateral RCC without any familial history
andassociatedsyndrome,andreportedtheironcologicaland
nephrological outcomes to underscore the clinical presen-
tation and transition of intervention. We therein described
2 patients recently treated with computerized-tomography-
guided percutaneous radiofrequency ablation therapy (RFA)2 Advances in Urology
for renal tumors emerging in the residual kidney after
surgery for sporadic bilateral RCC.
2. Patientsand Methods
We reviewed the clinical and pathological record between
January 1992 and December 2007 in the Department of
Urology, Niigata University Hospital, and associate institu-
tions. Five patients were found with renal masses in the
residual kidney following surgery for sporadic/nonfamilial
bilateral RCC. These masses were solid on CT, and were
thought most probably de novo or recurrent RCCs. Clinical
and pathological stages were determined according to the
International Union Against Cancer (UICC) classiﬁcation
of 2002 [4]; for cases in earlier years, those were reassessed
using this criterion. Clinical staging routinely included chest
radiograph and abdominal computerized tomography (CT).
All subjects for clinical interventions gave informed consent
to all patients. Informed consent to use the data for clinical
or basic researches was obtained from all the patients.
The procedure for the patients treated with RFA was
approved by a suitably constituted Ethics Committee of
Niigata University Hospital. RFA was performed with pre-
viously reported devices and techniques [5]. Brieﬂy, prophy-
lactic antimicrobials were administered 1hour before treat-
ment. An RF generator (Cool-tip Radiofrequency Ablation
System, Radionics, Burlington, Mass, USA) was used under
local anesthesia and sedation with intravenous phentanyl
citrate. The single cool-tip RF electrode was placed with a
real-time CT-guided method, referring to the tumor size,
shape, and localization to ablate whole tumor tissue. The
proximal margin of the tumor was initially ablated to
achieve suﬃcient ablation of the deeper central portion
of the kidney, and superﬁcial treatment was subsequently
performed. The target probe temperature was rendered at
100
◦C. Tumors were heated at 65
◦Ci na1 2 m i n u t ec y c l e
with a maximum electrical power of 50W, and a second
RF cycle was applied when the tissue temperature could not
be adequately maintained. After the probe was withdrawn,
RF energy was additionally given to the intraparenchymal
and perirenal needle tracks to minimize bleeding and
tumor cell dissemination. Dietary intake was started 3hours
after treatment, and limitations of activity were lifted
on the next day. Follow-up CT was performed every 3-
4 months for the initial 12months and thereafter every
6months.
3. Results
Patients and their characteristics are shown in Table 1.T h e
clinical presentation of these patients is summarized as
follows: patients’ age ranged between 42 and 62 (mean
53.4) years at the initial visit. One patient was female,
and the remaining 4 were male. Three patients were
asymptomatic, and the tumors were incidentally found on
abdominal ultrasonography or CT performed for other
purposes. Two patients were symptomatic, and presented
with hematuria and/or pyrexia. Two patients had syn-
chronous bilateral disease, and 3 had a metachronous tumor
4, 7, and 11years after primary radical nephrectomy. Of
the 2 patients with synchronous disease, one patient had
T1a in both sides and N0M0 disease, and one had T1b
and T1aN0M0 disease. In 3 patients with metachronous
bilateral RCC, the primary disease was T1bN0M0, T2N0M0,
and T1aN0M0, respectively; all of secondary tumors were
diagnosedasT1a.Thepatientswerefollowedpostoperatively
with chest roentgenogram/thoracic CT and abdominal CT
every 6months for the initial 3-4 years and thereafter
annually when they did not have a recurrence.
Theclinicalcourseandoutcomeofthe5patientsarepre-
sented in Table 2. Of the 2 patients with synchronous bilat-
eraldisease,onepatient underwentﬁrstradicalnephrectomy
for the tumor in one kidney and subsequently nephron-
sparing surgery for the other kidney; the other patient was
treated with nephron-sparing surgery/partial nephrectomy
for both kidneys in separate sessions. The 3 patients with
metachronous diseases received radical nephrectomy for
the primary disease, and the metachronously appearing
tumor in the contralateral kidney was treated with nephron-
sparing surgery. The pathological diagnoses of the 10 tumors
were conventional RCC G2, G2-dominant with G1, or G2-
dominant with G3. Surgical margins and lymph nodes were
pathologically negative for cancer cells in all the specimens.
The 5 patients had a recurrent solid mass in the residual
kidney on CT during the follow-up period for 16–88 (mean
46.8) months after last surgery, which was thought most
probably metachronous de novo or recurrent RCC (Table 2).
Of the 2 patients having a de novo tumor in earlier years
(1992–1999), one patient underwent excision of the residual
kidney, resulting in a dialysis-dependent status, and the
tumor was histologically conﬁrmed with RCC G2 (case
number 1 in Tables 1 and 2). The other patient was managed
with a conservative observation according to informed
consent (case number 2 in Tables). Although her course
was lost 29 months after recurrence in the residual kidney,
the tumor gradually enlarged during the observation period
(2.0cm to 3.0cm). Of the 3 patients in recent years (2000–
2007), one patient selected the conservative management,
and was alive with disease thereafter for 22months (case
number 3 in Tables); his tumor slightly enlarged during the
observation. The remaining 2 patients (case number 4 and
case number 5 in the tables) underwent CT-guided RFA, and
their courses are summarized as follows; the former patient
(case number 4) underwent radical nephrectomy for a
nonmetastaticT1bleftrenaltumor,pathologicallydiagnosed
as conventional RCC G2, when he was 62years old. Eleven
yearsaftersurgery,hereceivednephron-sparing surgeryfora
smallrightrenaltumorwithsamepathology.Sixteenmonths
after the second operation, a metastatic pancreatic lesion
was treated with surgery. It was pathologically diagnosed
with RCC G2-dominant with G3, and during the follow-
up period, a renal tumor most probably RCC measuring
3cm was found in the remaining right kidney (Figure 1(a)).
Because of his poor renal function (serum creatinine level of
2.2mg/dL, creatinine clearance of 28mL/min) and insecure
prognosis, the tumor was treated with RFA. The local tumor
shrank and did not enlarge postoperatively for 20 months
with his renal function preserved (serum creatinine level ofAdvances in Urology 3
Table 1: Patients, their characteristics at the initial visit, occurrence pattern of renal tumors, and surgical approaches.
Patient number Age (y.o.) Sex Leading symptom Stage Occurrence pattern Nephrectomy
Case 1 48 male hematuria T1b, T1a synchronous radical and partial
Case 2 54 female pyrexia T2, T1a metachronous radical and partial
Case 3 61 male none T1a, T1a metachronous partial and partial
Case 4 62 male none T1b, T1a metachronous radical and partial
Case 5 42 male none T1a, T1a synchronous partial and partial
All the patients had N0M0 disease at the initial visit or when the metachronous tumor emerged in the contralateral kidney. All the tumors were pathologically
diagnosed as conventional renal cell carcinoma (RCC) G2 or G2-dominant, and surgical margins in patients receiving partial nephrectomy were negative for
malignant tissue.
Table 2: Clinical course and outcome of the patients.
Patient number Disease-free duration
(months) Year of reoccurrence Management for
reoccurrence
Oncological
outcome
Nephrological
outcome
Case 1 33 1992 nephrectomy Disease-free for
longer than 10 years Dialysis dependent
Case 2 41 1995 Conservative
observation
Lost 29 months after
reoccurence Dialysis-free
Case 3 56 2005 Conservative
observation
Alive with disease
for 22 months Dialysis-free
Case 4 16 2006 RFA Alive with metastasis
for 20 months Dialysis-free
Case 5 88 2007 RFA Disease-free for 12
months Dialysis-free
Case number corresponds to that of Table 1. All the de novo or recurrent tumors in the residual kidney (reoccurrence) were diagnosed as T1a disease on
computerized tomography (CT). RFA, CT-guided radiofrequency ablation.
2.3mg/dL) (Figure 1(b)), although a new metastatic lesion
was found in the pancreatic head. The latter patient (case
number 5) was diagnosed as having bilateral T1a renal
tumors, when he was 42. Both tumors were managed by
nephron-sparing surgery, and were pathologically diagnosed
as RCC G2. Eighty-eight months after surgery, a solid renal
tumor of 2.5cm in size arose from the parenchyma center of
the left kidney (Figure 2(a)). The patient was also included
in criteria of chronic kidney disease with a serum creatinine
level of 1.5mg/dL (creatinine clearance of 36mL/min). Also,
he had poorly controlled epilepsy and severe alcoholic liver
injury, and received RFA for the de novo renal tumor
emerging metachronously. He was free of disease with no
evidence of local recurrence or metastases postoperatively
for 12 months (Figure 2(b)), and his renal function was well
preserved (serum creatinine level of 1.4mg/dL).
4. Discussion
The present report showed practice of the clinical course
and management in patients with de novo or recurrent renal
neoplasm in the residual kidney, who had received surgery
for sporadic bilateral RCC. Their disease history was very
long, and it is thought impossible to predict metachronous
occurrence of another renal lesion. Becker et al. reported the
long-term outcome in 101 patients with bilateral RCC, and
showed relatively favorable prognosis in them (probability
of the 5-, 10-, and 20-year cause-speciﬁc survival rate
was 91.9%, 79.1%, and 56.7%, resp.) [6]. Also, 57.4% of
these patients had metachronous occurrences, and they were
signiﬁcantly younger than those with synchronous disease
at diagnosis (median age 53.6 versus 58.7 years, P<. 05).
Although no patient in their series was described with de
novooccurrenceintheresidualkidneyafterbilateralsurgery,
more frequent incidence and younger age in metachronous
cases may suggest the need for treatment options in patients
under such situation as featured in the present report.
In the current report, one patient in earlier years received
excision of the residual kidney, and required hemodialysis.
Two patients did not accept hemodialysis, and selected the
conservative management. Thus, nephron-sparing as well as
oncological disease control is a matter of concern also in
the patient group featured herein. Hoﬀmann and associates
reported short-to-intermediate-term outcomes of patients
with RCC arising from a solitary kidney after nephrectomy,
who were treated with RFA [7]. All 10 patients in their
study had a history of nephrectomy, and the recurred
tumor size in the contralateral kidney ranged between 1.9
and 4.2cm (mean 2.7cm). No tumor recurrence or major
complication was observed postoperatively for 3–24 months,
and none of these patients became dialysis-dependent. In
their series, one patient developed another RCC and was
successfully treated with second RFA. Their data and our
results suggest that less invasive, nephron-sparing techniques
such as RFA or cryotherapy can preserve renal function
without compromising the oncological eﬃcacy, and RFA
may be a feasible option for patients with a de novo renal
tumorintheresidualkidney,whohavereceivedpriorsurgery4 Advances in Urology
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Figure 1: (a) T1-weighted magnetic resonance imaging showed
a solid mass measuring 3cm with heterogeneous intensity in the
residualrightkidney(casenumber4).(b)Thelocaltumorwaswell-
controlled for 20 months after CT-guided RFA.
for sporadic bilateral RCC. However, RFA for such cases has
several limitations. First, the therapeutic eﬃcacy of RFA is
assessed by radiographic ﬁndings, and it is impossible to
study pathological margin [8]. Second, RFA was undertaken
without biopsy for safer treatment, because the 2 patients
were highly complicated both anatomically and functionally
in kidney conditions, and also the imaging ﬁndings, clinical
course, and previous pathology strongly suggested presence
RCC in the residual kidney. Some previous studies have
suggested limitations in the eﬃcacy of biopsy followed by
ablative techniques [5, 7, 8]. Third, long-term oncological
outcomes are needed to draw a deﬁnite conclusion for the
exact utility of RFA in such patients.
In summary, we reported clinical practice in patients
with de novo or recurrent renal neoplasm, who had received
surgery for sporadic bilateral RCC. RFA could preserve renal
function without compromising the short-to-intermediate-
term oncological outcome, and may be a feasible option for
A
P
RL
IHX
LOC: 297
THK: 7
FFS
RD: 350
Tilt: 0
mA: 382
KVP: 120
Acq no: 1
51 of 74 (cm)
Z: 1
C: 50
W: 350
DFOV: 35 ×35cm
IM: 51 SE: 3
(a)
A
P
RL
LOC: 300
THK: 5
FFS
RD: 350
Tilt: 0
mA: 418
KVP: 120
Acq no: 4
70 of 95 (cm)
Z: 1
C: 60
W: 300
DFOV: 35 ×35cm
IM: 70 SE: 7
(b)
Figure 2: (a) Contrast-enhanced CT showed a solid tumor of
2.5cm in diameter with weak enhancement in the left kidney (case
number 5). (b) The tumor was replaced by low-density tissue
without enhancement following RFA, and he was free of disease
postoperatively for 12 months.
such patients, although further studies on the assessment for
its therapeutic eﬃcacy and biopsy technique are warranted.
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